News

Antimicrobial resistance (AMR) is one of the defining challenges of our time. It affects animal health and welfare in practice and has profound potential consequences for human health. As vets, we understand the pressure to reduce reliance on antibiotics while still safeguarding our patients. Animal Health Angels, a group of veterinary and animal health professionals supporting early-stage innovation, has announced recent backing for three companies developing practical solutions to tackle AMR and antibiotic use in clinical settings: Zonova, FluoretiQ and NoBACZ.

Marleybones, the UK’s premium dog-nutrition brand behind Pantry Fresh® meals, has closed a £2.5M funding round, and we’re proud to have taken part!

In a landmark moment for the veterinary industry, Molly Fiander, a Registered Veterinary Nurse (RVN) and founder of Management For Locums (MFL), has become the first vet nurse in the UK to secure investment as a solo founder for a veterinary technology company. This pioneering achievement marks a shift in how veterinary professionals are leading innovation in the sector.

Celebrating Global Entrepreneurship Week, Animal Health Angels is thrilled to announce its investment in SageTech Medical, which is at the forefront of innovative technology aimed at tackling environmental challenges associated with anaesthetic gas emissions.

The government has published the annual report for the Investing in Women Code, which now has 250 signatories. This Code aims to address the lack of investment in female entrepreneurs across all areas of financial services and the investment landscape. It has also expanded to include Limited Partners and Community Development Finance Institutions (CDFIs). Notably, the Investing in Women Code now accounts for 40% of UK Business Angels Association angel investment groups and 47% of venture capital deals.

Animal Health Angels are delighted to announce their most recent investment as a group into MI:RNA, the veterinary diagnostics company using cutting-edge technology and science to transform animal health diagnosis, as part of a $4 million in Series A funding round. Aiming to change the future of animal health treatments through improved, earlier diagnostics, the capital will be used to continue global growth plans and revolutionise animal health testing, improving diagnosis and wellness among the pet, agriculture and equine sectors. MI:RNA’s vision is to change the approach to disease diagnosis to improve animals’ outcomes. The merits of MI:RNA technology are scientifically reviewed and proven, winning numerous grants and awards.